Regentis Biomaterials Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
RGNT
- Share Price
-
$1.22
- (As of Tuesday Closing)
Regentis Biomaterials General Information
Description
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
Contact Information
Website
www.regentis.co.ilCorporate Office
- 60, Medinat Hyahudim
- Entrance C
- Herzlia Pituach 4676652
- Israel
Corporate Office
- 60, Medinat Hyahudim
- Entrance C
- Herzlia Pituach 4676652
- Israel
Regentis Biomaterials Stock Performance
As of 17-Nov-2026, Regentis Biomaterials’s stock price is $1.22. Its current market cap is $8.57M with 7.02M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.22 | $1.19 | $1.14 - $15.50 | $8.57M | 7.02M | 49.4K | -$2.46 |
Regentis Biomaterials Financials Summary
As of 30-Jun-2026, Regentis Biomaterials has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 18,613 | 77,982 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (12,704) | (13,324) | 4,972 | (3,959) |
| Net Income | (13,020) | (13,648) | 4,801 | (4,132) |
| Total Assets | 9,350 | 7,618 | 482 | 360 |
| Total Debt | 29 | 1,197 | 4,945 | 7,615 |
Regentis Biomaterials Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Regentis Biomaterials Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Regentis Biomaterials Patents
Regentis Biomaterials Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3018305-A1 | Treatments utilizing a polymer-protein conjugate | Inactive | 30-Mar-2016 | ||
| EP-3436076-A1 | Treatments utilizing a polymer-protein conjugate | Inactive | 30-Mar-2016 | ||
| US-20190083642-A1 | Treatments utilizing a polymer-protein conjugate | Inactive | 30-Mar-2016 | ||
| WO-2017168428-A1 | Treatments utilizing a polymer-protein conjugate | Inactive | 30-Mar-2016 | ||
| WO-2017168428-A9 | Treatments utilizing a polymer-protein conjugate | Inactive | 30-Mar-2016 | A61K47/6435 |
Regentis Biomaterials Signals
Regentis Biomaterials ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Regentis Biomaterials FAQs
-
When was Regentis Biomaterials founded?
Regentis Biomaterials was founded in 2004.
-
Where is Regentis Biomaterials headquartered?
Regentis Biomaterials is headquartered in Herzlia Pituach, Israel.
-
What is the size of Regentis Biomaterials?
Regentis Biomaterials has 7 total employees.
-
What industry is Regentis Biomaterials in?
Regentis Biomaterials’s primary industry is Therapeutic Devices.
-
Is Regentis Biomaterials a private or public company?
Regentis Biomaterials is a Public company.
-
What is Regentis Biomaterials’s stock symbol?
The ticker symbol for Regentis Biomaterials is RGNT.
-
What is the current stock price of Regentis Biomaterials?
As of 17-Nov-2026 the stock price of Regentis Biomaterials is $1.22.
-
What is the current market cap of Regentis Biomaterials?
The current market capitalization of Regentis Biomaterials is $8.57M.
-
What is Regentis Biomaterials’s annual earnings per share (EPS)?
Regentis Biomaterials’s EPS for 12 months was -$2.46.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process